StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report released on Friday. The firm issued a sell rating on the stock.
Syros Pharmaceuticals Price Performance
SYRS stock opened at $0.06 on Friday. Syros Pharmaceuticals has a 1 year low of $0.06 and a 1 year high of $6.93. The firm has a market capitalization of $1.65 million, a PE ratio of -0.02 and a beta of 1.31. The business has a 50 day simple moving average of $0.16 and a 200-day simple moving average of $0.85.
Institutional Trading of Syros Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC purchased a new stake in shares of Syros Pharmaceuticals in the fourth quarter valued at about $25,000. Exome Asset Management LLC grew its stake in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Featured Articles
- Five stocks we like better than Syros Pharmaceuticals
- What Are Some of the Best Large-Cap Stocks to Buy?
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Compound Interest and Why It Matters When Investing
- 3 ETFs to Ride the VIX Surge During Market Volatility
- How Can Investors Benefit From After-Hours Trading
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
